Microcap Ledger

Tickers · $GALT

Galectin Therapeutics Inc $GALT

By Microcap Ledger desk · CIK 0001133416

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Pharmaceutical Preparations
Headquarters
Norcross, GA
Fiscal year end
December 31
Shares outstanding
100,849,644 [10-Q 2026-08-14]
as of 2026-08-06

Sources: [10-K 2026-03-31]

What the company doesAI summary of filing

Galectin Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates that target galectin proteins, particularly galectin-3, for treatment of fibrotic diseases and cancer. The company's lead product candidate, belapectin (GR-MD-02), is a patented complex carbohydrate derived from plant-based starting materials and is being evaluated in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and head and neck cancer. Belapectin has completed Phase 2 trials and is currently in Phase 2b/3 development; the company reported results from its NAVIGATE trial in December 2024. The company generates no product revenue and funds its development through equity financing while pursuing strategic partnerships for advanced programs. [10-K 2026-03-31]

Segments: Belapectin for MASH cirrhosis, Belapectin for head and neck cancer immunotherapy, Small molecule galectin-3 inhibitors (Galectin Sciences LLC joint venture)

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026—−$14.16M −$6.30M$13.27M[10-Q 2026-08-14]
FY ended Dec 2025—−$30.84M −$23.88M$17.72M[10-K 2026-03-31]
FY ended Dec 2024—−$47.05M −$41.77M$15.12M[10-K 2026-03-31]
Quarterly cash burn
−$3.15M
Cash runway Estimate
~12.6 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-0862,761,825[10-Q 2024-11-14]
2025-03-0363,180,491[10-K 2025-03-31]
2025-05-0763,291,585[10-Q 2025-05-15]
2025-08-0764,060,262[10-Q 2025-08-14]
2025-11-0764,472,792[10-Q 2025-11-14]
2026-03-0265,827,448[10-K 2026-03-31]
2026-05-0865,856,898[10-Q 2026-05-15]
2026-08-06100,849,644[10-Q 2026-08-14]
Shelf registration
S-3 filed 2026-03-31; declared effective 2026-04-10 [S-3 2026-03-31]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-07-31Uihlein Richard Eexercise31,825,235$3.00[4 2026-08-04]
2026-07-31Uihlein Richard Eexercise2,550,932$4.05[4 2026-08-04]
2026-07-14Jamil Khurramexercise16,250$3.04[4 2026-07-16]
2026-07-14Jamil Khurramsell16,250$5.13[4 2026-07-16]
2026-06-29Shlevin Harold H.exercise22,268$1.23[4 2026-06-30]
2026-06-29Shlevin Harold H.sell22,268$5.04[4 2026-06-30]
2026-06-29Jamil Khurramexercise47,467$2.50[4 2026-06-30]
2026-06-29Jamil Khurramsell47,467$5.04[4 2026-06-30]
2026-06-26Shlevin Harold H.exercise7,732$1.23[4 2026-06-30]
2026-06-26Shlevin Harold H.sell7,732$5.00[4 2026-06-30]
2026-06-26Jamil Khurramexercise2,037$2.20[4 2026-06-30]
2026-06-26Jamil Khurramsell2,037$5.00[4 2026-06-30]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-10-02PRE 14AProxy statement
2026-08-148-KResults of operations
2026-08-1410-QQuarterly report
2026-08-0413D/ABeneficial ownership report (5%+ holder)
2026-08-048-KUnregistered sale of equity
2026-06-238-KRegulation FD disclosure
2026-05-158-KResults of operations
2026-05-1510-QQuarterly report
2026-03-31S-3Registration statement
2026-03-318-KResults of operations
2026-03-3110-KAnnual report
2026-03-178-KDirector or officer change

Facts as of . Small caps move fast; check the latest filings.